These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

814 related articles for article (PubMed ID: 24316260)

  • 1. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease.
    Lambert JE; Ramos-Roman MA; Browning JD; Parks EJ
    Gastroenterology; 2014 Mar; 146(3):726-35. PubMed ID: 24316260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesis.
    Lee JJ; Lambert JE; Hovhannisyan Y; Ramos-Roman MA; Trombold JR; Wagner DA; Parks EJ
    Am J Clin Nutr; 2015 Jan; 101(1):34-43. PubMed ID: 25527748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fructose as a key player in the development of fatty liver disease.
    Basaranoglu M; Basaranoglu G; Sabuncu T; Sentürk H
    World J Gastroenterol; 2013 Feb; 19(8):1166-72. PubMed ID: 23482247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease.
    Diraison F; Moulin P; Beylot M
    Diabetes Metab; 2003 Nov; 29(5):478-85. PubMed ID: 14631324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease.
    Softic S; Cohen DE; Kahn CR
    Dig Dis Sci; 2016 May; 61(5):1282-93. PubMed ID: 26856717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skeletal muscle insulin resistance promotes increased hepatic de novo lipogenesis, hyperlipidemia, and hepatic steatosis in the elderly.
    Flannery C; Dufour S; Rabøl R; Shulman GI; Petersen KF
    Diabetes; 2012 Nov; 61(11):2711-7. PubMed ID: 22829450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease.
    Smith GI; Shankaran M; Yoshino M; Schweitzer GG; Chondronikola M; Beals JW; Okunade AL; Patterson BW; Nyangau E; Field T; Sirlin CB; Talukdar S; Hellerstein MK; Klein S
    J Clin Invest; 2020 Mar; 130(3):1453-1460. PubMed ID: 31805015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of muscle insulin resistance with exercise reduces postprandial hepatic de novo lipogenesis in insulin resistant individuals.
    Rabøl R; Petersen KF; Dufour S; Flannery C; Shulman GI
    Proc Natl Acad Sci U S A; 2011 Aug; 108(33):13705-9. PubMed ID: 21808028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease.
    Fabbrini E; Mohammed BS; Magkos F; Korenblat KM; Patterson BW; Klein S
    Gastroenterology; 2008 Feb; 134(2):424-31. PubMed ID: 18242210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dietary sugar restriction reduces hepatic de novo lipogenesis in adolescent boys with fatty liver disease.
    Cohen CC; Li KW; Alazraki AL; Beysen C; Carrier CA; Cleeton RL; Dandan M; Figueroa J; Knight-Scott J; Knott CJ; Newton KP; Nyangau EM; Sirlin CB; Ugalde-Nicalo PA; Welsh JA; Hellerstein MK; Schwimmer JB; Vos MB
    J Clin Invest; 2021 Dec; 131(24):. PubMed ID: 34907907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic physiologic hyperinsulinemia impairs suppression of plasma free fatty acids and increases de novo lipogenesis but does not cause dyslipidemia in conscious normal rats.
    Koopmans SJ; Kushwaha RS; DeFronzo RA
    Metabolism; 1999 Mar; 48(3):330-7. PubMed ID: 10094109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes.
    Markova M; Pivovarova O; Hornemann S; Sucher S; Frahnow T; Wegner K; Machann J; Petzke KJ; Hierholzer J; Lichtinghagen R; Herder C; Carstensen-Kirberg M; Roden M; Rudovich N; Klaus S; Thomann R; Schneeweiss R; Rohn S; Pfeiffer AF
    Gastroenterology; 2017 Feb; 152(3):571-585.e8. PubMed ID: 27765690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Dietary Fructose Restriction on Liver Fat, De Novo Lipogenesis, and Insulin Kinetics in Children With Obesity.
    Schwarz JM; Noworolski SM; Erkin-Cakmak A; Korn NJ; Wen MJ; Tai VW; Jones GM; Palii SP; Velasco-Alin M; Pan K; Patterson BW; Gugliucci A; Lustig RH; Mulligan K
    Gastroenterology; 2017 Sep; 153(3):743-752. PubMed ID: 28579536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD).
    Ortiz-Lopez C; Lomonaco R; Orsak B; Finch J; Chang Z; Kochunov VG; Hardies J; Cusi K
    Diabetes Care; 2012 Apr; 35(4):873-8. PubMed ID: 22374640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease.
    Lomonaco R; Ortiz-Lopez C; Orsak B; Webb A; Hardies J; Darland C; Finch J; Gastaldelli A; Harrison S; Tio F; Cusi K
    Hepatology; 2012 May; 55(5):1389-97. PubMed ID: 22183689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver Pyruvate Kinase Promotes NAFLD/NASH in Both Mice and Humans in a Sex-Specific Manner.
    Chella Krishnan K; Floyd RR; Sabir S; Jayasekera DW; Leon-Mimila PV; Jones AE; Cortez AA; Shravah V; Péterfy M; Stiles L; Canizales-Quinteros S; Divakaruni AS; Huertas-Vazquez A; Lusis AJ
    Cell Mol Gastroenterol Hepatol; 2021; 11(2):389-406. PubMed ID: 32942044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities.
    Syed-Abdul MM; Parks EJ; Gaballah AH; Bingham K; Hammoud GM; Kemble G; Buckley D; McCulloch W; Manrique-Acevedo C
    Hepatology; 2020 Jul; 72(1):103-118. PubMed ID: 31630414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reproducibility of glucose, fatty acid and VLDL kinetics and multi-organ insulin sensitivity in obese subjects with non-alcoholic fatty liver disease.
    Magkos F; Fabbrini E; Korenblat K; Okunade AL; Patterson BW; Klein S
    Int J Obes (Lond); 2011 Sep; 35(9):1233-40. PubMed ID: 21179000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silibinin Capsules improves high fat diet-induced nonalcoholic fatty liver disease in hamsters through modifying hepatic de novo lipogenesis and fatty acid oxidation.
    Cui CX; Deng JN; Yan L; Liu YY; Fan JY; Mu HN; Sun HY; Wang YH; Han JY
    J Ethnopharmacol; 2017 Aug; 208():24-35. PubMed ID: 28648927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesencephalic astrocyte-derived neurotrophic factor ameliorates steatosis in HepG2 cells by regulating hepatic lipid metabolism.
    He M; Wang C; Long XH; Peng JJ; Liu DF; Yang GY; Jensen MD; Zhang LL
    World J Gastroenterol; 2020 Mar; 26(10):1029-1041. PubMed ID: 32205994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.